Case report| Volume 20, ISSUE 7, P795-798, July 1985

Persistent drug-induced parkinsonism

  • Thomas A. Aronson
    Address reprint requests to Dr. Thomas A. Aronson, State University of New York at Stony Brook, Health Sciences Center, T-10, Stony Brook, NY 11794.
    State University of New York at Stony Brook, Health Sciences Center, Stony Brook, NY, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ayd Jr, F.J.
        A survey of drug induced extra pyramidal reactions.
        JAMA. 1961; 175: 1054-1060
        • Ayd Jr, F.J.
        Haloperidol: Fifteen years of clinical experience.
        Dis Nerv Syst. 1972; 33: 459-469
        • Berkmeyer W.
        • et al.
        Deprenyl prolongs life of patients with Parkinson's disease.
        Mod Probl Pharmacopsychiatry. 1983; 19: 170-176
        • Demars J.P.C.A.
        Neuromuscular effects of long term phenothiazine medication, ECT, and leucotomy.
        J Nerv Ment Dis. 1966; 143: 73-79
        • Fleming P.
        • Makar H.
        • Hunter K.R.
        Levodopa in drug-induced extrapyramidal disorders.
        Lancet. 1970; ii: 1186
        • Freyhan F.A.
        Psychomotility and parkinsonism in treatment with neuroleptic drugs.
        Arch Neurol Psychiatry. 1957; 76: 56
        • Heikerita R.E.
        • et al.
        Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
        Nature. 1984; 311: 467-469
        • Marsden C.D.
        • Tarsy D.
        • Baldessarini R.L.
        Movement disorders in psychotic patients.
        in: Benson D.F. Blumer D. Psychiatric Aspects of Neurologic Disease. Grune and Stratton, Orlando, FL1975: 219-266
        • Rivera V.M.
        • Keichian A.H.
        • Oliver R.E.
        Persistent parkinsonism following neuroleptanalgesia.
        Anesthesiology. 1975; 42: 635-637
        • Schiele B.C.
        • et al.
        Comparison of low dose and high dose procedures in chlorpromazine therapy.
        Psychiat Q. 1959; 33: 252-259
        • Schmid W.R.
        • Jarcho L.W.
        Persistent dyskinesias following phenothiazine treatment.
        Arch Neurol. 1966; 14: 369-377
        • Schwab R.S.
        • England Jr, A.C.
        Parkinson syndromes due to various specific causes.
        Handbook of Clinical Neurology, Vol 6, Diseases of the Basal Ganglia. 1968; : 227-247